ANXA2 is a potential biomarker for cancer prognosis and immune infiltration: A systematic pan-cancer analysis

Background: Annexin A2 (ANXA2) belongs to the Annexin A family and plays a role in epithelial-mesenchymal transition, fibrinolysis, and other physiological processes. Annexin A2 has been extensively implicated in tumorigenesis and development in previous studies, but its precise role in pan-cancer r...

Descripción completa

Detalles Bibliográficos
Autores principales: Ning, Yijie, Li, Yufei, Wang, Hongqin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9877333/
https://www.ncbi.nlm.nih.gov/pubmed/36713082
http://dx.doi.org/10.3389/fgene.2023.1108167
_version_ 1784878344265793536
author Ning, Yijie
Li, Yufei
Wang, Hongqin
author_facet Ning, Yijie
Li, Yufei
Wang, Hongqin
author_sort Ning, Yijie
collection PubMed
description Background: Annexin A2 (ANXA2) belongs to the Annexin A family and plays a role in epithelial-mesenchymal transition, fibrinolysis, and other physiological processes. Annexin A2 has been extensively implicated in tumorigenesis and development in previous studies, but its precise role in pan-cancer remains largely unknown. Methods: We adopted bioinformatics methods to explore the oncogenic role of Annexin A2 using different databases, including the Cancer Genome Atlas (TCGA), the Genotype-Tissue Expression (GTEx) biobank, the Human Protein Atlas (HPA), the Gene Expression Profiling Interaction Analysis (GEPIA) and cBioPortal. We analyzed the differential expression of Annexin A2 in different tumors and its relationship with cancer prognosis, immune cell infiltration, DNA methylation, tumor mutation burden (TMB), microsatellite instability (MSI) and mismatch repair (MMR). Furtherly, we conducted a Gene Set Enrichment Analysis (GSEA) to identify the Annexin A2-related pathways. Results: Annexin A2 expression was upregulated in most cancers, except in kidney chromophobe (KICH) and prostate adenocarcinoma (PRAD). Annexin A2 showed a good diagnostic efficacy in twelve types of cancer. The high expression of Annexin A2 was significantly associated with a reduced overall survival, disease-specific survival and progression-free interval in seven cancers. The Annexin A2 expression was variably associated with infiltration of 24 types of immune cells in 32 tumor microenvironments. In addition, Annexin A2 expression was differently associated with 47 immune checkpoints, immunoregulators, DNA methylation, tumor mutation burden, microsatellite instability and mismatch repair in pan-cancer. Gene Set Enrichment Analysis revealed that Annexin A2 was significantly correlated with immune-related pathways in fifteen cancers. Conclusion: Annexin A2 widely correlates with immune infiltration and may function as a promising prognostic biomarker in many tumors, showing its potential as a target for immunotherapy in pan-cancer.
format Online
Article
Text
id pubmed-9877333
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-98773332023-01-27 ANXA2 is a potential biomarker for cancer prognosis and immune infiltration: A systematic pan-cancer analysis Ning, Yijie Li, Yufei Wang, Hongqin Front Genet Genetics Background: Annexin A2 (ANXA2) belongs to the Annexin A family and plays a role in epithelial-mesenchymal transition, fibrinolysis, and other physiological processes. Annexin A2 has been extensively implicated in tumorigenesis and development in previous studies, but its precise role in pan-cancer remains largely unknown. Methods: We adopted bioinformatics methods to explore the oncogenic role of Annexin A2 using different databases, including the Cancer Genome Atlas (TCGA), the Genotype-Tissue Expression (GTEx) biobank, the Human Protein Atlas (HPA), the Gene Expression Profiling Interaction Analysis (GEPIA) and cBioPortal. We analyzed the differential expression of Annexin A2 in different tumors and its relationship with cancer prognosis, immune cell infiltration, DNA methylation, tumor mutation burden (TMB), microsatellite instability (MSI) and mismatch repair (MMR). Furtherly, we conducted a Gene Set Enrichment Analysis (GSEA) to identify the Annexin A2-related pathways. Results: Annexin A2 expression was upregulated in most cancers, except in kidney chromophobe (KICH) and prostate adenocarcinoma (PRAD). Annexin A2 showed a good diagnostic efficacy in twelve types of cancer. The high expression of Annexin A2 was significantly associated with a reduced overall survival, disease-specific survival and progression-free interval in seven cancers. The Annexin A2 expression was variably associated with infiltration of 24 types of immune cells in 32 tumor microenvironments. In addition, Annexin A2 expression was differently associated with 47 immune checkpoints, immunoregulators, DNA methylation, tumor mutation burden, microsatellite instability and mismatch repair in pan-cancer. Gene Set Enrichment Analysis revealed that Annexin A2 was significantly correlated with immune-related pathways in fifteen cancers. Conclusion: Annexin A2 widely correlates with immune infiltration and may function as a promising prognostic biomarker in many tumors, showing its potential as a target for immunotherapy in pan-cancer. Frontiers Media S.A. 2023-01-12 /pmc/articles/PMC9877333/ /pubmed/36713082 http://dx.doi.org/10.3389/fgene.2023.1108167 Text en Copyright © 2023 Ning, Li and Wang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Genetics
Ning, Yijie
Li, Yufei
Wang, Hongqin
ANXA2 is a potential biomarker for cancer prognosis and immune infiltration: A systematic pan-cancer analysis
title ANXA2 is a potential biomarker for cancer prognosis and immune infiltration: A systematic pan-cancer analysis
title_full ANXA2 is a potential biomarker for cancer prognosis and immune infiltration: A systematic pan-cancer analysis
title_fullStr ANXA2 is a potential biomarker for cancer prognosis and immune infiltration: A systematic pan-cancer analysis
title_full_unstemmed ANXA2 is a potential biomarker for cancer prognosis and immune infiltration: A systematic pan-cancer analysis
title_short ANXA2 is a potential biomarker for cancer prognosis and immune infiltration: A systematic pan-cancer analysis
title_sort anxa2 is a potential biomarker for cancer prognosis and immune infiltration: a systematic pan-cancer analysis
topic Genetics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9877333/
https://www.ncbi.nlm.nih.gov/pubmed/36713082
http://dx.doi.org/10.3389/fgene.2023.1108167
work_keys_str_mv AT ningyijie anxa2isapotentialbiomarkerforcancerprognosisandimmuneinfiltrationasystematicpancanceranalysis
AT liyufei anxa2isapotentialbiomarkerforcancerprognosisandimmuneinfiltrationasystematicpancanceranalysis
AT wanghongqin anxa2isapotentialbiomarkerforcancerprognosisandimmuneinfiltrationasystematicpancanceranalysis